Breast conservation for T1-2 breast carcinomas - In Reply

被引：0
|
作者：
Ho, CM [1 ]
Chan, MCM
Cheung, WY
Hung, WK
机构：
[1] Kwong Wah Hosp, Dept Surg, Div Plast Surg, Hong Kong, Hong Kong, Peoples R China
[2] Kwong Wah Hosp, Dept Surg, Breast Ctr, Hong Kong, Hong Kong, Peoples R China
来源：
ANNALS OF SURGICAL ONCOLOGY | 2003年 / 10卷 / 08期
关键词：
D O I：
10.1245/ASO.2003.06.920
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：995 / 995
页数：1
相关论文
共 50 条
  • [31] Therapeutic value of postmastectomy radiation therapy for T1-2 breast cancer with 1-3 positive lymph nodes
    Kimura, Yuri
    Sasada, Shinsuke
    Goda, Noriko
    Kajitani, Keiko
    Emi, Akiko
    Masumoto, Norio
    Kadoya, Takayuki
    Okada, Morihito
    JOURNAL OF RADIATION ONCOLOGY, 2019, 8 (03) : 323 - 328
  • [32] Does postmastectomy radiation reduce mortality in women with stage T1-2 node-positive breast cancer?
    Heimann, R
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (09): : 442 - 443
  • [33] Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer?
    Kwak, Hee Yong
    Chae, Byung Joo
    Eom, Yong Hwa
    Hong, Young Ran
    Seo, Jae Beom
    Bae, Ja Seong
    Jung, Sang Seol
    Song, Byung Joo
    JOURNAL OF CHEMOTHERAPY, 2015, 27 (05) : 290 - 296
  • [34] Prognostic significance of TGFβ-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours
    Koumoundourou, Dimitra
    Kassimatis, Theodoros
    Zolota, Vasiliki
    Tzorakoeleftherakis, Evangelos
    Ravazoula, Panagiota
    Vassiliou, Vassilios
    Kardamakis, Dimitrios
    Varakis, John
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2613 - 2620
  • [35] Construction and validation of a risk prediction model for clinical axillary lymph node metastasis in T1-2 breast cancer
    Luo, Na
    Wen, Ying
    Zou, Qiongyan
    Ouyang, Dengjie
    Chen, Qitong
    Zeng, Liyun
    He, Hongye
    Anwar, Munawar
    Qu, Limeng
    Ji, Jingfen
    Yi, Wenjun
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [36] Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer.
    Sharma, Priyanka
    Kimler, Bruce F.
    Klemp, Jennifer R.
    Ward, Claire
    Connor, Carol Sue
    McGinness, Marilee
    Matthew, Joshua
    Mammen, Varghise
    Wagner, Jamie Lynn
    Amin, Amanda Leigh
    Fabian, Carol J.
    Jensen, Roy A.
    Godwin, Andrew K.
    Khan, Qamar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] SEGMENTAL-MASTECTOMY WITHOUT RADIOTHERAPY FOR T1 AND SMALL T2 BREAST CARCINOMAS
    MOFFAT, FL
    KETCHAM, AS
    ROBINSON, DS
    LEGASPI, A
    GHANDURMNAYMNEH, L
    HILSENBECK, S
    ARCHIVES OF SURGERY, 1990, 125 (03) : 364 - 369
  • [38] Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer
    Georges Vlastos
    Isabel T. Rubio
    Nadeem Q. Mirza
    Lisa A. Newman
    Ravi Aurora
    Julie Alderfer
    Aman U. Buzdar
    S. Eva Singletary
    Annals of Surgical Oncology, 2000, 7 : 581 - 587
  • [39] The Extent of Axillary Surgery Is Associated With Breast Cancer-specific Survival in T1-2 Breast Cancer Patients With 1 or 2 Positive Lymph Nodes: A SEER-Population Study
    Li, Shunrong
    Liu, Fengtao
    Chen, Kai
    Rao, Nanyan
    Xie, Yufen
    Su, Fengxi
    Zhu, Liling
    MEDICINE, 2016, 95 (14)
  • [40] Assessment of T stage in the multiple breast carcinomas
    Gong, G.
    Jo, J-H
    Lee, H. J.
    Kang, J.
    CANCER RESEARCH, 2012, 72
12345